Dihydroartemisinin for metabolic fatty liver disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether dihydroartemisinin, a malaria drug that may reduce liver fat, helps people with metabolic fatty liver disease. It is for adults aged 18 to 45 who have a fatty liver and at least one metabolic problem like overweight, high blood pressure, or diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have a fatty liver, shown by an ultrasound, CT scan, MRI, or a special test called FibroScan.
- You have at least one metabolic condition, such as overweight (BMI >= 24), high blood pressure, pre-diabetes or diabetes, high triglycerides, or low 'good' cholesterol.
- Your weight has been stable (no more than 5% change) in the last 3 months.
- You are not taking medications that can cause fatty liver (like steroids or certain other drugs) for more than 2 weeks in the past year.
- You do not drink too much alcohol (no more than 2 drinks per day for men, 1 for women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a digital health app designed to help people with metabolic-associated fatty liver disease (MAFLD). The app provides diet and exercise guidance to improve liver health.
This trial tests a medication called diacerein to see if it can help people with a type of fatty liver disease called MASLD. If you have fatty liver that is not caused by alcohol or other illnesses, this study may be a good fit for you.
This trial tests Ganzhixiao capsules for people with MAFLD (a type of fatty liver disease) who also have symptoms of 'damp heat' (like feeling heavy and sluggish). It aims to see if the capsules can help improve liver health.
This trial is testing a new ultrasound method to measure fat in the liver for people with metabolic fatty liver disease (MAFLD). It may help understand how well ultrasound can show liver fat compared to a liver biopsy or MRI.
This trial tests a new medication called ACT500 for people with fatty liver disease (MASLD). The goal is to see if it is safe and how the body processes it. You may be able to join if you have at least 10% liver fat, some liver scarring or damage, and certain metabolic risk factors like being overweight or having prediabetes.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.